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Abstract
Background: Babesia bovis is a tick-transmitted protozoan hemoparasite and the causative agent of bovine
babesiosis, a potential risk to more than 500 million cattle worldwide. The vaccines currently available are based on
attenuated parasites, which are difficult to produce, and are only recommended for use in bovines under one year
of age. When used in older animals, these vaccines may cause life-threatening clinical symptoms and eventually
death. The development of a multi-subunit recombinant vaccine against B. bovis would be attractive from an
economic standpoint and, most importantly, could be recommended for animals of any age. In the present study,
recombinant ectodomains of MSA-2a1, MSA-2b and MSA-2c antigens were expressed in Pichia pastoris yeast as
secreted soluble peptides.
Results: The antigens were purified to homogeneity, and biochemically and immunologically characterized. A
vaccine formulation was obtained by emulsifying a mixture of the three peptides with the adjuvant Montanide ISA
720, which elicited high IgG antibody titers against each of the above antigens. IgG antibodies generated against
each MSA-antigen recognized merozoites and significantly inhibited the invasion of bovine erythrocytes. Cellular
immune responses were also detected, which were characterized by splenic and lymph node CD4+ T cells
producing IFN-γ and TNF-α upon stimulation with the antigens MSA-2a1 or MSA-2c.
Conclusions: These data strongly suggest the high protective potential of the presented formulation, and we
propose that it could be tested in vaccination trials of bovines challenged with B. bovis.
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Background
Babesia bovis is a protozoan hemoparasite of the
phylum Apicomplexa and is the causative agent of
bovine babesiosis. In South America, the parasite is
transmitted by the common cattle tick (Rhipicephalus
microplus), and it is distributed mostly in the northeast
and northwest of Argentina, in the south-central regions
of Brazil, and in other tropical and subtropical regions
around the world. From an economic point of view,
bovine babesiosis is the most important disease of cattle
that is transmitted by arthropods and constitutes a
potential risk to more than 500 million cattle [1, 2].
Prospectively, an increased number of cattle will be at
risk of bovine babesiosis due to predicted expansion of
the vector’s habitat in response to global warming.
In hyperendemic areas, calves become infected at a
young age with B. bovis parasites and due to protective
mechanisms of innate immunity, they do not develop
clinical symptoms either upon infection or as adults.
Calves infected at a young age remain protected for life.
However, if the first exposure to the parasite occurs in
animals older than 1 year of age, an immune imbalance
is observed, which is characterized by pro-inflammatory
cytokine release and the development of serious clinical
symptoms, such as high temperature, sensory depres-
sion, anemia and uremia. Erythrocytes that are parasit-
ized by B. bovis are sequestered in brain capillaries,
leading to ischemia and neurological shock. In untreated
animals, the infection can rapidly lead to abortions and
death [2, 3].
Climatic factors, the erratic use of acaricides, and the
development of acaricide resistance can all lead to fluc-
tuations in the populations of B. bovis-infected ticks. In
such epidemiological situations, babesiosis outbreaks can
occur in adult cattle that were not naturally protected
through parasite transmission by ticks before 10 months
of age. In endemic areas, regular monitoring of the
immune status of herds is recommended. If 75–80% of
the 9–10-month-old cattle in a herd do not produce
antibodies against B. bovis, vaccination is mandatory to
prevent outbreaks [4]. Vaccination is also required when
adult bovines are transported from tick-free to tick-
endemic regions.
Currently available vaccines against bovine babesiosis
are based on live attenuated parasites that are either
amplified in vitro or in splenectomized calves. These
vaccines are produced in several countries, including
Argentina, Australia, Mexico, Brazil, Colombia, Israel
and South Africa. They are recommended for use in
bovines under a year of age and generally provide effect-
ive protection. However, if live vaccines are administered
to adult animals, clinical symptoms of babesiosis can
develop and lead to death if an infected animal is not
treated [1, 2].
The production of live vaccines is cumbersome and
time consuming and requires strict sanitary conditions
to avoid the co-transmission of pathogenic microorgan-
isms. Furthermore, vaccines must be kept chilled or
frozen, which is particularly inconvenient in the tropical
regions where they are often used. They also carry the
risk of lack of protection against resistant strains, as was
the case for Australian vaccines [5]. For these reasons,
the development of a recombinant subunit vaccine
would be a significant contribution to the control of
bovine babesiosis. This type of vaccine is safer and
simpler to produce on a large scale and therefore
reduces the cost of production. Additionally, its use
would not be limited to young cattle; it could be safely
extended for use in adult animals. Experimental studies
focused on the development of vaccines for B. bovis on
the basis of recombinant antigens are scarce and have
been limited to the use of prokaryotic expression
systems. In some cases, they have been unsuccessful at
using a single antigen [6, 7], whereas a formulation
containing two recombinant sub-dominant antigens
yielded promising results and provided a significant
reduction in the parasitemia of challenged animals [8].
However, these animals developed clinical signs and had
to receive treatment with parasiticide drugs. Likewise,
immunization of cattle with a mixture of three recombin-
ant merozoite surface antigens was not successful at
preventing clinical signs of the disease after challenge [9].
Antigens anchored by glycosylphosphatidyl inositol
(GPI) are candidates for vaccine development. In earlier
studies, Florin-Christensen et al. [10] and Suarez et al. [11]
described that B. bovis has at least five GPI-anchored anti-
gens, belonging to the family of Merozoite Surface Antigen
(MSA), which carry B-cell epitopes that are conserved
between strains. Specific antibodies to these proteins
prevent the invasion of erythrocytes and as such they play
a vital role in parasite propagation [11–14]. Additionally,
inhibition of GPI synthesis prevents in vitro growth of
parasites in erythrocytes, corroborating the importance of
these antigens in the process of invasion [15]. Furthermore,
the release of GPI-anchored proteins from parasite cell
membranes via treatment with phosphatidylinositol-
specific phospholipase C prevents erythrocyte invasion by
B. bovis merozoites [16]. As invasion of red blood cells is
crucial to the survival of the parasite, blocking the antigens
involved in this process may lead to protection. MSA-2c is
highly conserved among B. bovis geographical isolates and
therefore, together with its high immunogenicity during
infection of cattle, it has been applied to the development
of serological diagnostic methods [11, 13, 14, 17, 18].
Prokaryotic systems are widely used for recombinant
protein production. However, heterologous eukaryotic
proteins are not correctly modified, hampering their se-
cretion significantly. Moreover, this is often accompanied
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by protein misfolding and segregation into insoluble inclu-
sion bodies. Additionally, conformational epitopes, which
may be critical for the production of protective antibodies,
are likely to be absent in these proteins. Accordingly, the
expression of recombinant proteins using eukaryotic
systems may represent a long-term advantage in the effort
to solve these problems.
A heterologous expression system in Pichia pastoris
yeast has been used successfully in recent years. One of
the advantages of this system is the ability to strictly
regulate the expression of heterologous proteins and
their secretion to the extracellular medium, facilitating
their subsequent purification [19]. Additionally, in many
cases, proteins retain their biological activity, making
this approach useful for vaccine development [20, 21].
To generate a novel vaccine formulation against
babesiosis, the ectodomains of MSA-2a1, MSA-2b and
MSA-2c were produced as soluble recombinant proteins
in Pichia pastoris. To test the potential of these vaccine
candidates, immunization of mice with formulations of
individual recombinant antigens that included the adju-
vant Montanide ISA 720, and formulations comprising
all three antigens and the adjuvant, were performed.
Humoral and T-cell mediated immune responses were
studied, and the ability of the immune sera to inhibit
merozoite invasion in erythrocytes was evaluated.
Methods
Synthesis, cloning, and yeast expression
Synthetic genes encoding ectodomain amino acid residues
22–284 of MSA-2a1, residues 22–260 of MSA-2b and resi-
dues 25–239 of MSA-2c were synthetized by GenScript
USA, Inc. (Piscataway, NJ, USA), with codon optimization
to improve expression in P. pastoris. The amino acid
sequences were based on MSA-2a1 (GenBank AAL15425),
MSA-2b (GenBank AAL15427) and MSA-2c (GenBank
AAL15428) of B. bovis. To prevent unwanted glycosyla-
tion, potential N-glycosylation sites were altered by using
substitute amino acids. Constructs were designed to in-
clude appropriate restriction sites and a carboxyl-terminal
hexa-histidine tag (His6) to enable purification. The
synthetic genes that were cloned into the pUC57 vector
were removed by digestion with an NotI enzyme mix
(New England Biolabs, Ipswich, MA, USA) and subcloned
into the NotI site of the P. pastoris expression vector
pPIC9K (Invitrogen, Carlsbad, CA, USA). This expression
vector contains a nucleotide sequence encoding the α-
factor signal peptide of Saccharomyces cerevisiae to enable
protein secretion, the AOX1 promoter for the control of
gene expression, and the HIS4 gene for selection of
recombinant yeast clones. Clones were selected that
contained each gene in the correct orientation. Plasmids
were linearized with SalI and were transformed into the
GS115 strain (his4−) of P. pastoris by electroporation.
Clones that were transformed with either plasmid pPIC9K-
BbMsa2a1, pPIC9K-BbMsa2b or pPIC9K-BbMsa2c were
screened for high copy-number integration by G418 selec-
tion; of these clones, two were resistant to 2–4 mg/ml of
G418. Based on an immunoblotting analysis using an anti--
His6 mAb, clones that were secreting high levels of each re-
combinant protein and which possessed a Mut+ phenotype
were selected.
The expression and purification of the recombinant
proteins was performed as described with several
modifications [22]. A Mut+ transformant was initially
grown overnight in 2 l of BMGY medium (1% w/v yeast
extract, 2% w/v peptone, 1.34% w/v yeast nitrogen base
without amino acids, 4 × 10-5% w/v biotin, 1% w/v
glycerol, and 0.1 M potassium phosphate, pH 6.0) at
28–30 °C with vigorous shaking. The cells were
harvested, resuspended in 400 ml BMMY (BMGY with
glycerol replaced by 0.5% v/v methanol) and incubated
again for 72 h. Methanol was added to a final concentra-
tion of 1% v/v every 24 h. After induction for 72 h, the
cells were removed by centrifugation, and the culture
supernatant was concentrated by ultrafiltration with an
Amicon Ultracel 30,000 MWCO membrane (Millipore,
Massachussets, USA) and extensively dialyzed at 4 °C
against 20 mM sodium phosphate buffer/0.2 M NaCl,
pH 8.0. The supernatant was applied to a column HisTrap
FF coupled to a FPLC ÄKTA prime plus (GE Healthcare,
Chicago, USA), which was previously equilibrated with
20 mM sodium phosphate/0.5 M NaCl, pH 8.0. Bound
proteins were eluted with a 0 to 500 mM imidazole
(Sigma-Aldrich, St. Louis, MO, USA) gradient in wash
buffer (20 mM sodium phosphate/0.5 M NaCl/1 mM
PMSF/10% glycerin, pH 8.0). Fractions containing protein
were detected by SDS-PAGE and Coomassie blue staining,
pooled, and used in a second-purification step by anionic
exchange chromatography using Q FF resin coupled to a
FPLC ÄKTA prime plus (GE Healthcare, Chicago, USA).
The protein was eluted using a 0 to 1 M NaCl linear
gradient and analyzed by SDS-PAGE. The peaks corre-
sponding to each recombinant protein that had a high
degree of purity were collected and dialyzed against
phosphate-buffered saline (PBS). The protein concentra-
tion was determined by the Bradford method (BioRad,
Richmond, CA, USA) using bovine serum albumin (BSA,
Sigma-Aldrich, St. Louis, MO, USA) as a standard.
Purified proteins were analyzed by MALDI-TOF MS
using a Microflex LT system (Bruker Daltonics, Bremen,
Germany) and by reverse-phase high-performance liquid
chromatography (RP-HPLC) using a Vydac C18 column
(4.6 × 250 mm; 300 μm particle size) coupled to an HPLC
LCMS-2020 LC/MS system (Shimadzu, Kyoto, Japan).
The HPLC procedure was performed at room
temperature (RT) (c.25 °C) using a binary gradient of 0.1%
trifluoroacetic acid (TFA, Solvent A) and 0.1% TFA in a
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9:1 (v/v) solution of acetonitrile:water (Solvent B) with a
two-step solvent gradient starting at 0 to 20% and
followed by 20 to 100%, at a rate of 1 ml/min for 40 min.
The elution was monitored with a UV-Visible absorbance
detector (Shimadzu SPD M20A) at 220 and 280 nm.
Circular dichroism
Circular dichroism (CD) was performed using a JASCO-
J815 spectropolarimeter (Jasco, Tokyo, Japan) at 25 °C.
Recombinant proteins were diluted to a concentration of
10 μM in PBS and loaded into a 5-mm quartz cuvette.
Far-UV measurements (4 scans) were performed over
wavelengths of 250–190 nm at intervals of 0.1 nm with
a 1 nm bandwidth and 1 s response time. The spectra
presented are the average of four scans, and the data
obtained were reported as values of molar ellipticity
[Ɵ]MRW (deg × cm
2 × dmol-1). A baseline measurement
with buffer was subtracted from each spectrum. The
secondary structure was estimated by computer analysis
using the method of Raussens et al. [23] (http://perry.
freeshell.org/raussens.html).
Mice and immunization protocol
Female C57BL/6 mice at 6- to 8-weeks old were
purchased from CEDEME (Federal University of São
Paulo, Brazil) and used in all of the experiments. The
immunogenicity of the recombinant proteins was evalu-
ated in mice using homologous prime-boost protocols
(protein prime/protein boost). Immunizations with the
recombinant proteins were performed via the subcuta-
neous (s.c.) route with 1 or 10 μg of each protein
emulsified in the presence of the adjuvant Montanide
ISA 720 (Seppic, Puteaux, France), using proportions of
30/70 (vol/vol) of protein/adjuvant. Three injections
were performed at three weeks apart. A volume of 50 μl
was injected into each footpad (first dose) and a final
volume of 100 μl was injected at the base of the tail
(second and third doses). After each immunization,
blood was collected from the tail, and the sera were
analyzed for the presence of antibodies against each
recombinant protein.
Immunological assays
Immunoblotting analysis
Proteins were fractionated by 12% SDS-PAGE under
reducing conditions and were transferred from the gel to
nitrocellulose membranes (Hybond N, GE Healthcare,
Chicago, USA) with the aid of a Mini Trans-Blot appar-
atus (BioRad, Richmond, CA, USA). The immunoblot was
essentially performed as described [24]. The membranes
were incubated with mouse monoclonal anti-histidine tag
antibodies (anti-His tag, GE Healthcare, Chicago, USA) at
a final dilution of 1:1,000. After 1 h at RT, membranes
were washed, and goat anti-mouse Immunoglobulin G
(IgG) coupled to peroxidase was added to the membranes
at a final dilution of 1:2,000 (Sigma-Aldrich, St. Louis,
MO, USA). After 1 h incubation at RT, the reaction was
developed using a chemiluminescence detection assay
(ECL, GE Healthcare, Chicago, USA).
Determination of mouse antibody titers against B. bovis
recombinant protein
Antibodies against each recombinant protein in mouse
sera were detected by enzyme-linked immunosorbent
assay (ELISA), essentially as described [24]. The recom-
binant proteins were employed as solid phase-bound
antigens (200 ng/well), and a volume of 50 μl of each
solution was added to each well of a 96-well plate. After
overnight incubation at RT, plates were washed with a
solution of PBS and 0.05% Tween-20 (PBS-T) and
blocked with a solution of PBS, 2.5% (w/v) skimmed
milk and 2.5% BSA for 2 h at 37 °C. Serial dilutions of
murine polyclonal sera (100 μl) were added to wells in
duplicates, followed by incubation for 1 h at RT. After
washing with PBS-T, 50 μl aliquots of peroxidase-labeled
goat anti-mouse IgG (Sigma-Aldrich, St. Louis, MO,
USA), diluted 1:1,000, were added to each well. Detec-
tion by chemiluminescence was carried out as above.
Anti-MSA titers were determined based on the highest
dilution of sera that yielded an A492 higher than 0.1. For
detection of IgG subclass responses, secondary anti-
bodies specific to mouse IgG1, IgG2b, and IgG2c were
used (Southern Technologies, Chattanooga, Tennessee,
USA). Results are expressed as the mean values of IgG
titers (log10) ± standard error (SEM) that were detected
2 weeks after each immunizing dose.
Indirect immunofluorescence assay
Immunofluorescence assays were performed as described
[18]. Briefly, smears were prepared using a suspension of
B. bovis (BboS2P pathogenic strain, Argentina)-parasitized
erythrocytes (13% infection) that were cultured in vitro
and diluted 1:3 in PBS containing 1% BSA. The prepara-
tions were fixed with cold methanol for 15 min and
blocked with 3% BSA in PBS for 30 min at 37.5 °C in a
humidified incubator. Sera from mice immunized with the
recombinant proteins (dilution 1:50) were applied to the
slides and incubated for 1 h. Slides were then washed 3
times with PBS before the addition of either anti-mouse
IgG conjugated to fluorescein isothiocyanate (FITC)
(Sigma-Aldrich, St. Louis, MO, USA), which was diluted
1:500 in PBS containing 3% BSA, or 4’,6-Diamidino-2-Phe-
nylindole Dihydrochloride (DAPI, Invitrogen, Carlsbad,
CA, USA). Positive anti-rMSA-2c (13) and negative (non
immunized mice) reference sera were included on each
slide. Binding was visualized using a Nikon TS 100
epifluorescence microscope.
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Invasion inhibition assay
Babesia bovis merozoites of the Argentine S2P patho-
genic strain (BboS2P) were cultured in vitro on bovine
erythrocytes, as described previously [16]. Growth was
monitored by microscopic observation of Giemsa-
stained smears. Inhibition of merozoite invasion of
erythrocytes was carried out as described for the strain
R1A [13] with some modifications. Briefly, aliquots of
BboS2P-infected bovine erythrocyte cultures were incu-
bated in triplicate in 96-well plates either with pools of
control mouse sera (from five mice, ELISA titer < 102) or
with immune sera (from five mice each, ELISA titers >
104), diluted 1:10 in culture medium, at 37 °C in a 5%
CO2 atmosphere. The packed volume of bovine erythro-
cytes was 5% (v/v), and the initial percentage of parasit-
ized erythrocytes (PPE) was approximately 1%. All sera
had been heat-inactivated for 30 min at 56 °C. At 24 h
and 48 h, supernatants (80% of the total volume of each
well) were replaced with fresh culture medium contain-
ing the corresponding murine sera. Percentages of para-
sitized erythrocytes were determined at 72 h by
microscopic examination of 2500 erythrocytes in
Giemsa-stained smears that were prepared from each
well.
Cytokine measurement
To determine the intracellular expression of cytokines
interferon gamma (IFN-γ) and tumor necrosis factor
(TNF-α), intracellular cytokine staining (ICS) was used.
Splenocytes and lymph node cells (popliteal and in-
guinal) that were collected from C57BL/6 mice 12 days
after the third dose were treated with ammonium-
chloride-potassium buffer. ICS was evaluated following
the in vitro culture of splenocytes in the presence or
absence of antigenic stimulus. Cells were washed 3 times
in RPMI 1640 medium (pH 7.4) and re-suspended in cell
culture medium consisting of RPMI 1640 medium
(pH 7.4) that was supplemented with 10 mM HEPES,
0.2% sodium bicarbonate, 59 mg/l of penicillin, 133 mg/l
of streptomycin, and 10% fetal bovine serum (Hyclone,
Logan, USA). Cell viability was evaluated using 0.2% try-
pan blue exclusion dye. Cell density was adjusted to 5 ×
106 cells/ml in cell culture medium containing anti-
CD28 (2 μg/ml), BDGolgiPlug (10 μg/ml) and monensin
(5 μg/ml). In half of the cultures, either a final concen-
tration of 10 μg/ml of the indicated recombinant
proteins or 2 μg/ml of Concanvalin A (ConA, Sigma-Al-
drich, St. Louis, MO, USA) were added. The cells were
cultivated in V-bottom 96-well plates (Corning, Tewks-
bury, MA, USA) in a final volume of 200 μl in duplicate,
at 37 °C in a humid environment containing 5% CO2.
After a 12 h incubation, cells were stained for surface
markers with PerCP-Cy5.5-labeled anti-CD4 (clone
RM4-5), or PECy7-labeled CD8 (clone 53–6.7), on ice
for 20 min. To detect IFN-γ and TNF-α by intracellular
staining, cells were then washed twice in PBS/0.5% BSA/
2 mM EDTA, fixed and permeabilized with BD perm/
wash buffer (BD Biosciences, San Jose, CA, USA). After
being washed twice with BD perm/wash buffer, cells
were stained for intracellular markers using APC-labeled
anti-IFN-γ (Clone XMG1.2) and PE-labeled anti-TNF-α
(clone MP6-XT22). Finally, cells were washed twice with
BD perm/wash buffer and fixed in 1% PBS-
paraformaldehyde. At least 300,000 cells were acquired
on a BD FACSCanto II flow cytometer and then ana-
lyzed with FlowJo 8.7 software (http://www.flowjo.com/).
To measure the number of cells secreting IFN-γ,
splenocytes and lymph node cells collected from immu-
nized C57BL/6 mice were used for enzyme-linked
immunospot (ELISPOT) assays. These assays were
performed as in previous studies [25].
Statistical analysis
Values were log transformed and compared using One-
Way ANOVA followed by Tukey’s HSD tests (http://
faculty.vassar.edu/lowry/VassarStats.html). Differences w
ere considered significant when P-values were < 0.05.
Results
Expression, purification, and biochemical characterization
of rMSA-2a1, rMSA-2b, and rMSA-2c
For secreted expression in the methylotrophic yeast Pichia
pastoris, constructs based on the codon-optimized gene
sequences of MSA-2a1, MSA-2b and MSA-2c were used.
The amino acid sequences of the expressed ectodomains
of each protein are shown in Fig. 1a. MSA-2b and MSA-
2c amino acid sequences have one and three putative
N-linked glycosylation (NxS/T) sites, respectively, and
substitute amino acids (NxS/T to AxS/T) were introduced
to remove these sites. The final constructs also encoded
an N-terminal hexa-histidine tag for Ni2+-chelating
chromatography. The synthetic msa-2a1, msa-2b and
msa-2c genes were sub-cloned in frame with the yeast
α-factor secretion signal peptide into the expression
vector pPIC9K.
The generated recombinant proteins were soluble and
secreted into the extracellular medium. Figure 1b shows
SDS-PAGE analyses of supernatants originated from
yeast clones for each recombinant protein (left panel).
The presence of recombinant proteins was demonstrated
by immunoblotting using anti-His6-mAb (right panel).
After purification, yields of up to 20 mg/l of culture
were obtained for rMSA-2a1, rMSA-2b and rMSA-2c. A
high protein purity was confirmed by reverse-phase
chromatography on a C-18 column by observation of
single peaks, as shown in Fig. 2a, c, e.
To investigate the secondary structures of the recom-
binant products, far-UV CD spectroscopy was performed
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(Fig. 2b, d, f ). In all cases, CD spectra were consistent with
folded proteins. The following estimated percentages of
α-helix, anti-parallel β-sheet, parallel β-sheet and β-turn
for each protein were found: (i) MSA-2a1-His6: 46%
α-helix, 19% β-sheet, 12.5% β-turn; (ii) MSA-2b-His6:
8.9% α-helix, 24.4% β-sheet, 12.5% β-turn; (iii) MSA-2c-
His6: 34% α-helix, 13% β-sheet, 12.5% β-turn.
Immunogenic properties of rMSA-2a1, rMSA-2b and
rMSA-2c in mice
Initially, mice were immunized either with each indi-
vidual recombinant protein or with all three recombin-
ant proteins combined using a 1 μg dose per mouse.
However, the antibody titers did not reach desirable
levels to all antigens (data not shown). Thus, in order to
increase immunogenicity, we decided to immunize mice
with 10 μg of each recombinant protein per mouse per
dose or a combination of all three recombinant proteins,
according to the schedule described in Fig. 3a. The com-
parative immunogenicities of each animal group (n = 5)
were determined by the mean values + SE of the serum
IgG antibody titers against each of the recombinant
proteins, as estimated by ELISA.
Antibody titers of up to ~ 105 against the homologous
protein were observed in mice immunized with rMSA-
2a1 (Fig. 3b). The antibody titers against the other
Fig. 1 Expression of B. bovis merozoite surface antigens as soluble recombinant proteins in P. pastoris. a Schematic representation of MSA-2a1-His6,
MSA-2b-His6 and MSA-2c-His6. Codon-optimized genes were synthesized and contained nucleotides corresponding to the indicated primary protein
structures. Amino acids indicated in red represent modifications that were made to avoid N-glycosylation. b Genes were expressed as fusion recombinant
proteins containing a hexa-histidine tag (His6) in Pichia pastoris yeast. The supernatants of yeast clones expressing each recombinant merozoite antigen
were separated by SDS-PAGE under reducing conditions, stained with Coomassie Blue (left panel) and immunoblotted on nitrocellulose membranes using
antibodies against the His6 tag (right panel). Lanes 1 and 4: MSA-2a1-His6; Lanes 2 and 5: MSA-2b-His6; Lanes 3 and 6: MSA-2c-His6
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recombinant proteins were also high, in the range of ~
105 or ~ 104 for rMSA-2b or rMSA-2c, respectively
(Fig. 3c, d).
The immunization of mice with rMSA-2b elicited high
antibody titers to all three recombinant proteins (~ 105,
Fig. 3b-d). Likewise, mice immunized with rMSA-2c
displayed significant antibody titers to all three recom-
binant proteins (~ 105, Fig. 3b-d). Most relevant for
vaccine development was the fact that mice immunized
with the three recombinant proteins admixed responded
extremely well to all three recombinant proteins, with
antibody titers that were higher than 105 with respect to
both rMSA-2a1 and rMSA-2b (Fig. 3b, c) and even
higher with respect to rMSA-2c (~106, Fig. 3d). Their
antibody titers were the highest observed out of all of
the groups of immunized mice to each of the recombin-
ant proteins, demonstrating that there was an additive
effect (Fig. 3b-d). These antibody titers were long-lasting
and could be detected until day 125 after the first dose.
As in the previous experiment, control mice injected
with adjuvant alone did not present specific detectable
antibodies (Fig. 3b-d).
IgG sub-classes were also estimated. Except for Gr. 1
(adjuvant only), all other mouse groups developed high
IgG1 antibody titers to all three recombinant proteins
(Fig. 4a-c).
In conclusion, the three B. bovis recombinant proteins
adjuvanted in Montanide ISA 720 were highly immuno-
genic in mice.
Babesia bovis merozoite recognition and ability to inhibit
parasite invasion with rMSA-2a1, rMSA-2b and rMSA-2c
immune sera
As a next step, we investigated if antibodies against the
three recombinant proteins reacted with B. bovis mero-
zoites using immunofluorescence assays. We observed
Fig. 2 Biochemical characterization of recombinant B. bovis merozoite antigens. rMSA-2a1, rMSA-2b and rMSA-2c were analyzed by RP-HPLC (a, c and
e). A main peak was detected in each case, denoting a high level of purity. The circular dichroism spectrum of each recombinant protein was recorded
from 190 to 250 nm using a JASCO-J815 spectropolarimeter (b, d and f). The plots represent the mean residue ellipticity of the recombinant proteins
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Fig. 3 Specific antibody responses in mice immunized with recombinant B. bovis merozoite antigens. Immunization of C57BL/6 mice and measurement
of antibody titers by ELISA was carried out according to the timeline described in a. Mice were divided in five groups (n= 5 in each group) and
immunized with three doses of the following: (1) Montanide ISA 720; (2) Montanide ISA 720 plus rMSA-2a1 (10 μg/dose/mouse); (3) Montanide ISA 720
plus rMSA-2b (10 μg/dose/mouse); (4) Montanide ISA 720 plus rMSA-2c (10 μg/dose/mouse); (5) Montanide ISA 720 plus a protein mix (rMSA-2a1,
rMSA-2b, rMSA-2c; 10 μg of each protein per mouse). Serum IgG antibody titers against B. bovis merozoite antigens were determined by ELISA using each
recombinant protein in the plate. b rMSA-2a1. c rMSA-2b. d rMSA-2c. The results represent the mean values ± standard error obtained for each group
Fig. 4 IgG sub-classes of specific antibodies in mice immunized with recombinant B. bovis merozoite antigens. Mice were immunized as described in
Fig. 3. Antibody titers of each IgG subclass (IgG1, IgG2b, IgG2c) to each B. bovis merozoite antigen were determined by using a pool of sera from each
mouse group. a rMSA-2a1. b rMSA-2b. c rMSA-2c. These data represent one of two independent experiments
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that the sera from each of the groups of mice immu-
nized with the recombinant proteins reacted with mero-
zoites of B. bovis at 1:100 dilutions (Fig. 5b-d). Antibody
recognition was specific, as control sera from mice
immunized with adjuvant only were not reactive, even at
a 1:50 dilution (Fig. 5a).
We subsequently evaluated the immune sera for its
ability to inhibit merozoite invasion of bovine erythro-
cytes in culture. The presence of immune sera collected
from mice immunized with rMSA-2a1, rMSA-2b or
rMSA-2c led to significative specific inhibitions of 39, 28
and 49% of erythrocyte invasion, respectively (Fig. 6,
ANOVA: F(4,10) = 33.66, P <0.001 for rMSA-2a1 and
rMSA-2c; P = 0.008 for rMSA-2b). However, most
relevant for vaccine development was the fact that sera
obtained from mice vaccinated with all three recombin-
ant proteins admixed inhibited parasite invasion by 68%
(Fig. 6, ANOVA: F(4,10) = 33.66, P < 0.001). This inhib-
ition was specific because sera from mice injected with
adjuvant only failed to inhibit parasite invasion of
erythrocytes.
Cell-mediated immune responses to rMSA-2a1, rMSA-2b
and rMSA-2c of B. bovis
To determine whether immunization with the recombin-
ant proteins elicited T cell-mediated immune responses,
spleen and lymph node cells were collected from 4 mice
immunized either with mixture of three proteins
Fig. 5 Indirect immunofluorescence assay for the recognition of native MSA-2a1, MSA-2b and MSA-2c. Smears of B. bovis-infected erythrocytes (CC) were
incubated with pools of sera from mice immunized with each recombinant protein (1:100 dilutions) or control sera (1:50 dilution). Reactions were detected
with FITC-conjugated anti-mouse IgG antibodies (FITC). Nuclei were detected by DAPI staining (DAPI). Slides were observed with 400× magnification.
Scale-bars: 10 μm
Gimenez et al. Parasites & Vectors  (2016) 9:577 Page 9 of 13
emulsified with adjuvant or with adjuvant alone. Cells were
stimulated ex vivo with recombinant proteins, after which
IFN-γ and TNF-α expression was measured by intra-
cellular staining (ICS) and the number of IFN-γ-secreting
cells was assessed by ELISPOT. The results showed that
splenic cells of mice immunized with the mixture of three
proteins (either 1 μg or 10 μg of each protein per dose per
mouse) and re-stimulated in vitro with rMSA-2a1 or
rMSA-2c had a significant increase in the frequencies of
CD4+ T cells expressing IFN-γ and IFN-γ/TNF-α (Fig. 7a,
b; ANOVA: F(3,12) = 6.89, P = 0.009 for CD4
+ IFN-γ+ cells
and F(3,12) = 9.25, P = 0.015 for CD4
+ IFN-γ+/TNF-α+
cells). The same significant increase in the frequencies of
CD4+ T cells was observed when splenic cells were re-
stimulated with rMSA-2c (Fig. 7a, b; ANOVA: F(3,12) =
6.89, P = 0.045 for CD4+ IFN-γ+ cells and F(3,12) = 9.25, P
= 0.019 for CD4+ IFN-γ+/TNF-α+ cells). In contrast, we
could not detect a significant increase in the IFN-γ+ or
IFN-γ+TNF-α+ cells upon re-stimulation with rMSA-2b in
vitro or in CD8+ T cells (Fig. 7a-c; ANOVA: F(3,12) = 6.89,
P = 0.874 for CD4+ IFN-γ+ cells and F(3,12) = 9.25, P =
0.383 for CD4+ IFN-γ+/TNF-α+ cells).
Similar results were observed when lymph node cells
were re-stimulated with the recombinant proteins. Cells
of mice immunized with mixture of proteins (either 1 μg
or 10 μg of each protein per dose per mouse) and re-
stimulated in vitro with rMSA-2a1 or rMSA-2c had a
significant increase in the frequencies of CD4+ T cells
expressing IFN-γ and IFN-γ/TNF-α (ANOVA: F(3,12) =
29.11, P = 0.021 for rMSA-2a1 and P < 0.001 for rMSA-
2c) (Additional file 1: Figure S1a).
In parallel, these cells were assayed via ELISPOT.
Similar to the ICS experiments, significant differences in
the frequencies of IFN-γ-producing cells were detected
when we analyzed the splenic or lymph node cells (Add-
itional file 1: Figure S1b, c respectively) of mice immu-
nized with the mixture of proteins (either 1 μg or 10 μg
per dose per mouse). A significantly higher number of
cells from mice immunized with the protein mix secreted
IFN-γ upon in vitro re-stimulation with rMSA-2a1
(ANOVA: F(3,12) = 29.23, P = 0.002 for splenic cells and
F(3, 12) = 43.53, P < 0.001 for lymph node cells) or rMSA-
2c (ANOVA: F(3,12) = 29.23, P < 0.001 for splenic cells and
F(3,12) = 43.53, P < 0.001 for lymph node cells). In contrast,
these cells failed to secrete this cytokine upon stimulation
with rMSA-2b (ANOVA: F(3,12) = 29.23, P = 0.989 for
splenic cells and F(3,12) = 43.53, P = 0.251 for lymph node
cells). We concluded that, following protein immunization,
T cell-mediated immunity to the recombinant proteins
MSA-2a1 or MSA-2c of B. bovis can be detected in the
spleens and lymph nodes of the immunized mice.
Discussion
Our study describes a new multi-epitope vaccine formu-
lation against B. bovis based on three soluble recombin-
ant proteins produced in P. pastoris yeast. This platform
optimized protein expression, facilitated purification and
yielded high quantities of folded recombinant proteins at
Fig. 6 Inhibition of erythrocyte invasion by sera from mice immunized with the different antigen formulations. Mice were immunized as described in
Fig. 3. Pooled sera of the different mice groups were added (1:10, final concentration) in triplicate to wells containing B. bovis-infected erythrocytes that
were cultured in vitro. Percentages of parasitized erythrocytes (PPE) were evaluated in Giemsa-stained smears. The results are expressed as the mean PPE
± standard error values that were obtained after 72 h in each condition. The results are representative of two independent experiments. Asterisks denote
statistically significant differences in PPE: * P < 0.001 for rMSA-2a1 sera; P = 0.008 for rMSA-2b sera; P < 0.001 for rMSA-2c sera; P < 0.001 for the sera from
mixture of three proteins; compared to cultures incubated with medium only; and ¥ P = 0.006 compared to cultures incubated with sera from mice im-
munized with the mixture of three proteins
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a high degree of purity. The predominance of α-helix in
MSA-2a1 and MSA-2c may be essential to their func-
tioning and is compatible with the predicted structures
of the native proteins [14]. This fact could be important
for vaccine development as thus far recombinant
proteins produced in bacteria have failed to provide pro-
tection upon challenge when used as vaccines in cattle
[2]. The recombinant MSA-2b protein showed a higher
degree of a random secondary structure than the others.
Accordingly, this protein was less immunogenic than
rMSA-2a1 and rMSA-2c, both in B-cell and T-cell medi-
ated responses. These results support the idea of a close
relationship between protein folding and protein func-
tion. The successful use of the P. pastoris expression
Fig. 7 Cell-mediated immunity of mice immunized with recombinant MSA antigens. C57BL/6 mice were immunized with three doses, 21 days apart, of
a mixture containing either 1 μg or 10 μg of each protein/dose (per mouse) emulsified in Montanide ISA 720. Control mice received adjuvant only.
Splenic cells of 4 mice were cultured in the presence of anti-CD28, monensin and brefeldin-A with or without the recombinant proteins or ConA, as
indicated. After 12 h, cells were stained with anti-CD4, anti-CD8, anti-IFN-γ, and anti-TNFα. a Total frequencies (%) of CD4+ or CD8+ cells stained for TNF-α
and IFN-γ b and c Mean frequencies of 4 mice ± SE of IFN-γ+ CD4 or CD8 cells, respectively. The results are representative of two experiments. Asterisks
denote statistically significant (P = 0.009 for rMSA-2a1 and P = 0.045 for rMSA-2c) higher frequencies of cells from mice immunized with the mixture of
proteins when compared to cells from mice injected with adjuvant only
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system may be significant for vaccine development
efforts against B. bovis because there are other mole-
cules, such as apical membrane antigen-1 or rhoptry-
associated protein-1, that could also be expressed and
purified applying this strategy [26–28].
For our multi-epitope vaccine formulation, we selected
three MSAs. These antigens are GPI-anchored mem-
brane proteins and carry B-cell epitopes, which are
conserved between strains, and they target specific anti-
bodies that prevent the invasion of erythrocytes [11–14].
Interestingly, our work clearly shows immunological
cross-reactivity between the three MSAs tested, which
can be partially explained on the basis of amino acid
similarities. Although all N-glycosylation sites have been
removed in the recombinant proteins, we cannot
exclude the possibility of these proteins sharing post-
translational modifications as source of antigenic simi-
larities. However, immunological cross-reactivity was not
observed when these proteins were expressed in a
prokaryotic system, where proteins are mostly expressed
misfolded [10]. Thus, we suggest that this observation is
likely due to the presence of B-cell epitopes that are
generated in the P. pastoris system [14] and would be
absent in a prokaryotic system.
Supporting these earlier studies, we observed that
immune sera obtained from mice immunized with our
vaccine formulation inhibited the growth of parasites in
vitro in bovine erythrocytes. Although it is so far
unknown the specific role of MSAs proteins during
parasite invasion, the neutralization of some surface
proteins through antibodies could interfere with the
invasion process of erythrocytes. As this is an important
step for parasite survival, these antibodies may be
capable to control parasitemia in vivo, which in turn
may alleviate disease symptoms. Our results show that
MSA-specific immune sera are able to partially
neutralize parasite invasion in vitro, suggesting a poten-
tial participation of those proteins during cell invasion.
Importantly, the immunization with a mixture of all
three MSAs improved the neutralization activity of
immune sera, probably due to a broader breadth of the
recognized parasitic epitopes.
In addition to invasion-inhibitory antibodies, the im-
portance of Th1 cells in the development of immunity
against B. bovis has been proposed. In cattle infected
with B. bovis and B. bigemina, the main cellular response
is Th1 type, and it was hypothesized that such response
could induce protection against challenge. In this case,
the Th1 response would be mediated by effector CD4+ T
cells that secrete IFN-γ and provide help for the
production of protective antibodies [3, 29]. In this study,
the frequencies of IFN-γ and IFN-γ/TNF-α-expressing
cells were quantified. Our vaccine formulation elicited
easily detectable frequencies of CD4+ T cells expressing
IFN-γ and IFN-γ/TNF-α in the spleens and lymph nodes
of immunized mice. In the case of MSA-2b, the ratio
IgG1/IgG2 = 1 found in mice immunized with this
recombinant protein should indicate a balanced Th1/
Th2 response. We were not able to detect cellular
responses elicited by this antigen; however, we believe
that it is worth to maintain MSA-2b in the vaccine
formulation, as a significative invasion inhibition by sera
from mice immunized with MSA-2b only was observed.
Our results are encouraging to test this vaccine in cattle,
as it remains to be evaluated whether this formulation which
elicited such response in mice, will be able to elicit enough
neutralizing MSA-specific antibodies and/or T cell-mediated
responses to obtain a complete protection in cattle.
Conclusion
In summary, we have shown that a multi-epitope vaccine
is immunogenic to CD4+T cells and can generate high
levels of antibodies and T cell-mediated immunity. This
formulation will be used in future work to determine
whether it provides protection against bovine babesiosis.
Additional file
Additional file 1: Figure S1. Cell-mediated immunity of mice
immunized with recombinant MSAs. C57BL/6 mice were immunized as
described in Fig. 7. Splenic or lymph node cells of these mice were cultured
in the presence or absence of the recombinant proteins or ConA, as
indicated. a The lymph node cells of these mice were cultured in the
presence of anti-CD28, monensin and brefeldin-A with or without the
recombinant proteins or ConA, as indicated. After 12 h, cells were stained
with anti-CD4 and anti-IFN-γ. The results are expressed as the mean ± SE of
the total frequency (%) of CD4+ IFN-γ + cells from 4 mice. b, c After 48 h,
IFN-γ secreting cells (spot forming cells, SFC) were estimated by ELISPOT
assay. The results are representative of two experiments and are expressed
as number of SFC per 5 × 105 splenic (b) or lymph node (c) cells obtained
from 4 mice. Asterisks denote statistically significant (b: P = 0.002 for rMSA-
2a1; P < 0.001 for rMSA-2c; and c: P < 0.001 for rMSA-2a1; P < 0.001 for
rMSA-2c) higher frequencies of number of cells from mice immunized with
the mixture of proteins
compared to cells from mice injected with adjuvant only. (TIF 49 kb)
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